Biocept Appoints RSM as Independent Auditor
June 27 2022 - 8:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces the appointment
of RSM US LLP (“RSM”) as its independent registered public
accounting firm effective June 24, 2022. RSM was recently ranked
the fifth largest accounting, tax and consulting services firm in
the U.S. for the 16th straight year by Accounting Today.
RSM replaces Mayer Hoffman McCann P.C. (“MHM”), which notified
the company on April 7, 2022 of its decision to decline to stand
for re-appointment as the company’s independent registered public
accounting firm. The decision by MHM was not the result of any
disagreement with the company. MHM’s audit reports on the company’s
financial statements as of and for the years ended December 31,
2021 and 2020 did not contain an adverse opinion or a disclaimer of
opinion and were not qualified or modified as to uncertainty, audit
scope or accounting principles.
About RSM US LLP
RSM’s purpose is to deliver the power of being understood to our
clients, colleagues and communities through world-class audit, tax
and consulting services focused on middle market businesses. The
clients we serve are the engine of global commerce and economic
growth, and we are focused on developing leading professionals and
services to meet their evolving needs in today’s ever-changing
business environment. RSM US LLP is the U.S. member of RSM
International, a global network of independent audit, tax and
consulting firms with 51,000 people across 123 countries. For more
information, visit rsmus.com, like us on Facebook, follow us on
Twitter and/or connect with us on LinkedIn.
About Biocept, Inc.
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. Biocept has developed and is commercializing
the CNSide™ cerebrospinal fluid assay that detects cancer cells
that have metastasized to the central nervous system. Biocept’s
patented Target Selector™ technology captures and quantitatively
analyzes CSF tumor cells for tumor-associated molecular markers,
using technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health
efforts. For more information, visit www.biocept.com.
Forward-Looking Statements Disclaimer
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to the ability of
CNSide to impact life expectancy and quality of life, our ability
to establish CNSide as the new standard of care for the diagnosis
of patients with suspected cancer metastasis to the CNS, our
ability to expand our CSF testing menu for additional tumor types
and biomarkers in the future, and our ability to provide physicians
with clinically actionable information for treating and monitoring
patients diagnosed with a variety of cancers, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this news release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC at http://www.sec.gov/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220627005172/en/
Investor and Media Contact: LHA Investor Relations Jody
Cain Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024